International Research in Chinese Medicine

Objective To explore the clinical efficacy and application value of Professor Xu Yongchang's treatment of impotence with kidney deficiency syndrome using Zanyudan combined with Wuzi Yanzong Wan. Methods 156 patients with impotence with kidney deficiency syndrome admitted to our hospital (April 2024 to April 2025) were randomly divided into two groups (78 cases in each group): the treatment group received Zanyudan combined with Wuzi Yanzong Wan with modifications, while the control group received the original Zanyudan formula. Changes in the International Index of Erectile Function-5 (IIEF-5) score and TCM syndrome score before and after treatment were observed, and the total clinical effective rate was statistically analyzed. Results Before treatment, the TCM syndrome scores and IIEF-5 scores of the two groups were similar (P>0.05). After treatment, the TCM syndrome scores of both groups decreased while the IIEF-5 scores increased. Furthermore, the treatment group showed a lower TCM syndrome score and a higher IIEF-5 score (P<0.05). Compared with the control group, the total effective rate of the treatment group was significantly higher (94.87% vs. 79.49%, P<0.05). Conclusion Professor Xu Yongchang's use of Zanyudan combined with Wuzi Yanzong Wan to treat impotence with kidney deficiency syndrome can effectively improve patients' erectile function and alleviate kidney deficiency-related symptoms, demonstrating definite clinical efficacy.

Zanyudan; Wuzi yanzong wan; Impotence; Kidney deficiency syndrome; IIEF-5 score; TCM syndrome